Elise Coulson, MD
Allergy & Immunology · Asheville, NCNPI 1073993788
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Alk-abello, Inc at 50.8% of the total. Reporting peaked in 2022 at $8,839 and has fallen 75.6% since, to $2,156 in 2025.
Across 353 payments — averaging $44.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alk-abello, Inc$8K
- GSK$1K
- Novartis$1K
- Sanofi$967
- AstraZeneca$814
- Takeda Pharmaceuticals U.S.A., Inc.$408
- plus $3K from 23 others
What the payments were for
- Consulting fees$1,2098%
- Speaking & faculty fees$6,50041%
- Travel & lodging$9956%
- Food & beverage$6,96544%
- Education$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alk-abello, Inc | 14 | $8,010 |
| GSK | 94 | $1,444 |
| Novartis | 5 | $1,356 |
| Sanofi | 52 | $967 |
| AstraZeneca | 33 | $814 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $408 |
| CSL Behring | 15 | $406 |
| Regeneron Healthcare Solutions, Inc. | 17 | $352 |
| ARS Pharmaceuticals Operations, Inc. | 18 | $335 |
| Biocryst US Sales Co., LLC | 13 | $313 |
| Amgen | 20 | $291 |
| Grifols USA, LLC | 9 | $234 |
| Genentech USA, Inc. | 8 | $140 |
| Hospira, Inc. | 5 | $113 |
| Pfizer | 7 | $111 |
| Kaleo, Inc. | 5 | $71 |
| Optinose US, Inc. | 4 | $71 |
| Blueprint Medicines Corporation | 3 | $54 |
| Pharming Healthcare, Inc. | 2 | $39 |
| Cycle Pharmaceuticals Inc | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Ionis Pharmaceuticals, Inc. | 1 | $31 |
| Seqirus USA Inc | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| ADMA Biomanufacturing LLC | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| AbbVie | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Covis Pharma GmbH | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,765 in reported general payments places this provider in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 34 | $126,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $106,904 |
| NucalaMepolizumab | 27 | $97,231 |
| Dupixent PenDupilumab | 15 | $56,131 |
| Epinephrine | 81 | $17,428 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $12,062 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,242 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,063 |
| Arnuity ElliptaFluticasone Furoate | 23 | $6,208 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $4,753 |
| Azelastine Hcl | 116 | $3,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,684 |
| Wixela InhubFluticasone Propion/Salmeterol | 25 | $2,410 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 13 | $2,310 |
| Ipratropium Bromide | 58 | $1,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,444 | $218,584214 claims |
| AstraZenecaSymbicort | $814 | $12,06245 claims |
| Boehringer IngelheimSpiriva Respimat | $20 | $8,06316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Asheville
- William McCannAsheville$486K
- David BrownAsheville$129K
- Christopher CopenhaverAsheville$88K
- David CypcarAsheville$40K
- Jordan SmallwoodAsheville$13K
- John van WyeAsheville$11K
- Catherine CranfordAsheville$7K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.